47 results on '"Michael Shi"'
Search Results
2. Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US
- Author
-
Fatemeh Asad Zadeh Vosta Kolaei, Beilei Cai, Hemanth Kanakamedala, Julia Kim, Vitalii Doban, Shiyu Zhang, and Michael Shi
- Subjects
next-generation sequencing ,PD-L1 ,chemotherapy ,immuno-oncology therapy ,real world outcomes ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundMET exon 14 skipping mutation (METex14) is observed in ~3% of non-small cell lung cancer (NSCLC) cases and has been shown to be an independent poor prognostic factor associated with shorter overall disease-specific survival. Broad molecular testing can identify this biomarker in patients with advanced NSCLC (aNSCLC) and allow patients to be matched with the appropriate targeted therapy. This study examines biomarker testing patterns and clinical outcomes of chemotherapy and immuno-oncology (IO) monotherapy in aNSCLC patients with METex14.MethodsA descriptive retrospective study was conducted using the Flatiron Health–Foundation Medicine Inc. (FMI) clinico-genomic database. Patients with METex14 aNSCLC treated with systemic therapies were included in the biomarker testing analysis. The duration from specimen collection to reported results was assessed for PD-L1– and METex14-tested patients. Clinical outcomes were assessed in patients treated with chemotherapy or IO monotherapy. First-line (1L) and second-line (2L) real-world progression-free survival (rw-PFS) were estimated using Kaplan-Meier analysis.ResultsOf 91 METex14 patients eligible for the biomarker testing analysis, 77% and 60% received PD-L1 and FMI next-generation sequencing (NGS) testing within 3 months post aNSCLC diagnosis. Of those assessed for both PD-L1 and METex14 (n=9), the median duration between specimen collection and reporting was 1 week shorter for PD-L1 than for FMI NGS. Median 1L rw-PFS was 5.7 months (95% CI, 4.6-7.1) and 2.4 months (95% CI, 1.4-3.2) in patients receiving 1L chemotherapy (n=59) and IO monotherapy (n=18), with 3-month 1L rw-PFS rates of 78% and 33%. Median 2L rw-PFS was 3.5 months (95% CI, 1.9-11.1) and 4.7 months (95% CI, 2.8-12.9) in patients receiving 2L chemotherapy (n=16) and IO monotherapy (n=23), with 3-month 2L rw-PFS rates of 54% and 67%.ConclusionsThe median time from biopsy to test results appears 1 week shorter for PD-L1 than for FMI NGS. Chemotherapy and IO monotherapy were the most common regimens utilized but with limited PFS.
- Published
- 2022
- Full Text
- View/download PDF
3. On the numerical performance of finite-difference-based methods for derivative-free optimization.
- Author
-
Hao-Jun Michael Shi, Melody Qiming Xuan, Figen öztoprak, and Jorge Nocedal
- Published
- 2023
- Full Text
- View/download PDF
4. A Noise-Tolerant Quasi-Newton Algorithm for Unconstrained Optimization.
- Author
-
Hao-Jun Michael Shi, Yuchen Xie, Richard H. Byrd, and Jorge Nocedal
- Published
- 2022
- Full Text
- View/download PDF
5. A Distributed Data-Parallel PyTorch Implementation of the Distributed Shampoo Optimizer for Training Neural Networks At-Scale.
- Author
-
Hao-Jun Michael Shi, Tsung-Hsien Lee, Shintaro Iwasaki, Jose Gallego-Posada, Zhijing Li 0001, Kaushik Rangadurai, Dheevatsa Mudigere, and Michael Rabbat
- Published
- 2023
- Full Text
- View/download PDF
6. Adaptive Finite-Difference Interval Estimation for Noisy Derivative-Free Optimization.
- Author
-
Hao-Jun Michael Shi, Yuchen Xie, Melody Qiming Xuan, and Jorge Nocedal
- Published
- 2022
- Full Text
- View/download PDF
7. On the numerical performance of finite-difference-based methods for derivative-free optimization
- Author
-
Hao-Jun Michael Shi, Melody Qiming Xuan, Figen Oztoprak, and Jorge Nocedal
- Subjects
Control and Optimization ,Applied Mathematics ,Software - Published
- 2022
- Full Text
- View/download PDF
8. Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma
- Author
-
Qi Zhang, Jian Zhang, Haijun Zhong, Ying Yuan, Lei Yang, Qingyuan Zhang, Dongmei Ji, Jifang Gong, Jing Li, Zhenling Yao, Chuan Qi, Jianming Wang, Lingmin Lu, Michael Shi, Xueming Qian, Lin Shen, Jian Li, and Xichun Hu
- Subjects
Cancer Research ,Oncology ,Immunology ,Immunology and Allergy - Published
- 2023
- Full Text
- View/download PDF
9. Data from Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- Author
-
José Baselga, Alejandro Yovine, Diana Graus Porta, Andrea Kay, Yong Zhang, Michael Shi, Stephanie Deudon, John W. Smith, Hope Rugo, Nicholas Turner, Sara A. Hurvitz, Jose M. Perez-Garcia, Florence Dalenc, Mario Campone, Thomas Bachelot, and Fabrice André
- Abstract
Purpose: Fibroblast growth factor receptor 1 (FGFR1) and FGFR2 amplifications are observed in approximately 10% of breast cancers and are related to poor outcomes. We evaluated whether dovitinib (TKI258), an inhibitor of FGFR1, FGFR2, and FGFR3, presented antitumor activity in FGFR-amplified breast cancers.Experimental Design: Preclinical activity of dovitinib was evaluated in both breast cancer cell lines and an FGFR1-amplified xenograft model (HBCx2). Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2–negative metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status. FGFR1 amplification was assessed by silver in situ hybridization. Preplanned retrospective analyses assessed predictive value of FGFR1, FGFR2, and FGF3 amplifications by quantitative PCR (qPCR).Results: Dovitinib monotherapy inhibits proliferation in FGFR1- and FGFR2-amplified, but not FGFR-normal, breast cancer cell lines. Dovitinib also inhibits tumor growth in FGFR1-amplified breast cancer xenografts. Eighty-one patients were enrolled in the trial. Unconfirmed response or stable disease for more than 6 months was observed in 5 (25%) and 1 (3%) patient(s) with FGFR1-amplified/HR-positive and FGFR1-nonamplified/HR-positive breast cancer. When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway–amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway–amplified breast cancer.Conclusion: Dovitinib showed antitumor activity in FGFR-amplified breast cancer cell lines and may have activity in breast cancers with FGF pathway amplification. Clin Cancer Res; 19(13); 3693–702. ©2013 AACR.
- Published
- 2023
- Full Text
- View/download PDF
10. Supplementary Figure 1 from Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- Author
-
José Baselga, Alejandro Yovine, Diana Graus Porta, Andrea Kay, Yong Zhang, Michael Shi, Stephanie Deudon, John W. Smith, Hope Rugo, Nicholas Turner, Sara A. Hurvitz, Jose M. Perez-Garcia, Florence Dalenc, Mario Campone, Thomas Bachelot, and Fabrice André
- Abstract
PDF file - 20K, Dovitinib effectively targets FGFR1 in vivo. FGF23 levels were measured from plasma taken at baseline and during dovitinib treatment in 18, 33, and 20 patients from the FGFR1+/HR+, FGFR1-/HR+, and FGFR1-/HR- patient groups, respectively. Error bars represent the 95% confidence intervals.
- Published
- 2023
- Full Text
- View/download PDF
11. Supplementary Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
- Author
-
Dong-Wan Kim, Michael Shi, Fabrice Branle, Yuanbo Song, Pilar Cazorla Arratia, Felipe K. Hurtado, Pilar Garrido, Chong-Jen Yu, Mark McKeage, Margarita Majem, Rita Chiari, Sergey Orlov, Chao-Hua Chiu, Patrick Y. Wen, Heather A. Wakelee, Martin J. van den Bent, Erin M. Bertino, Fabrice Barlesi, and Laura Q.M. Chow
- Abstract
Supplementary Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
- Published
- 2023
- Full Text
- View/download PDF
12. Supplementary Table 1 from Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- Author
-
Bernard Escudier, Andrea Kay, Michael Shi, Julie Chang, Paramita Sen, Jean-Charles Soria, Daniel Castellano, Andrea Harzstark, Jürgen E. Gschwend, Chia-Chi Lin, Jose A. Lopez-Martin, and Eric Angevin
- Abstract
PDF file - 49K, Supplemental Table 1. Criteria for defining dose-limiting criteria
- Published
- 2023
- Full Text
- View/download PDF
13. Supplementary Figure 1 from Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
- Author
-
Eric Angevin, Michael Shi, Matthew Squires, Nicoletta Pirotta, Sarah Beall, Andrea Harzstark, Jürgen E. Gschwend, Chia-Chi Lin, Daniel Castellano, Yen-Chuan Ou, Alain Ravaud, Viktor Grünwald, and Bernard Escudier
- Abstract
PDF file - 57KB, Supplemental Figure 1 contains the longitudinal plot of model-adjusted fold change from baseline for plasma VEGF.
- Published
- 2023
- Full Text
- View/download PDF
14. Supplementary Figure from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
- Author
-
Dong-Wan Kim, Michael Shi, Fabrice Branle, Yuanbo Song, Pilar Cazorla Arratia, Felipe K. Hurtado, Pilar Garrido, Chong-Jen Yu, Mark McKeage, Margarita Majem, Rita Chiari, Sergey Orlov, Chao-Hua Chiu, Patrick Y. Wen, Heather A. Wakelee, Martin J. van den Bent, Erin M. Bertino, Fabrice Barlesi, and Laura Q.M. Chow
- Abstract
Supplementary Figure from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
- Published
- 2023
- Full Text
- View/download PDF
15. Supplementary Figure Legend, Table 1 from Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- Author
-
José Baselga, Alejandro Yovine, Diana Graus Porta, Andrea Kay, Yong Zhang, Michael Shi, Stephanie Deudon, John W. Smith, Hope Rugo, Nicholas Turner, Sara A. Hurvitz, Jose M. Perez-Garcia, Florence Dalenc, Mario Campone, Thomas Bachelot, and Fabrice André
- Abstract
PDF file - 61K, Growth Inhibition in FGFR1- and FGFR2-Amplified Cell Lines.
- Published
- 2023
- Full Text
- View/download PDF
16. Data from Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
- Author
-
Eric Angevin, Michael Shi, Matthew Squires, Nicoletta Pirotta, Sarah Beall, Andrea Harzstark, Jürgen E. Gschwend, Chia-Chi Lin, Daniel Castellano, Yen-Chuan Ou, Alain Ravaud, Viktor Grünwald, and Bernard Escudier
- Abstract
Purpose: Fibroblast growth factor (FGF) signaling regulates tumor growth and vascularization and partly mediates antiangiogenic escape from VEGF receptor (VEGFR) inhibitors. Dovitinib (TKI258) is a tyrosine kinase inhibitor (TKI) that inhibits FGF receptor (FGFR), VEGFR, and platelet-derived growth factor receptor, which are known drivers of antiangiogenic escape, angiogenesis, and tumor growth in renal cell carcinoma (RCC).Experimental Design: Patients with advanced or metastatic RCC were treated with oral dovitinib 500 mg/day (5-days-on/2-days-off schedule). The study population was enriched for patients previously treated with a VEGFR TKI and an mTOR inhibitor.Results: Of 67 patients enrolled, 55 patients (82.1%) were previously treated with ≥1 VEGFR TKI and ≥1 mTOR inhibitor (per-protocol efficacy set). The 8-week overall response rate and disease control rate in this population were 1.8% and 52.7%, respectively. Disease control rate during the entire study period was 56.4% (50.9% ≥4 months). Median progression-free survival and overall survival in the entire population were 3.7 and 11.8 months, respectively. Pharmacodynamic analyses demonstrated dovitinib-induced inhibition of VEGFR (as determined by increased levels of placental growth factor and decreased levels of soluble VEGFR2) and FGFR (as determined by increased FGF23 serum measures). The most frequently reported treatment-related adverse events of all grades included nausea (65.7%), diarrhea (62.7%), vomiting (61.2%), decreased appetite (47.8%), and fatigue (32.8%).Conclusion: Dovitinib was shown to be an effective and tolerable therapy for patients with metastatic RCC who had progressed following treatment with VEGFR TKIs and mTOR inhibitors. Clin Cancer Res; 20(11); 3012–22. ©2014 AACR.
- Published
- 2023
- Full Text
- View/download PDF
17. Supplementary Figure Legend from Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
- Author
-
Eric Angevin, Michael Shi, Matthew Squires, Nicoletta Pirotta, Sarah Beall, Andrea Harzstark, Jürgen E. Gschwend, Chia-Chi Lin, Daniel Castellano, Yen-Chuan Ou, Alain Ravaud, Viktor Grünwald, and Bernard Escudier
- Abstract
PDF file - 20KB
- Published
- 2023
- Full Text
- View/download PDF
18. Supplementary Table 1 from Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
- Author
-
Eric Angevin, Michael Shi, Matthew Squires, Nicoletta Pirotta, Sarah Beall, Andrea Harzstark, Jürgen E. Gschwend, Chia-Chi Lin, Daniel Castellano, Yen-Chuan Ou, Alain Ravaud, Viktor Grünwald, and Bernard Escudier
- Abstract
PDF file - 22KB, Supplemental Table 1 contains the pharmacokinetic results from the study.
- Published
- 2023
- Full Text
- View/download PDF
19. Data from Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- Author
-
Bernard Escudier, Andrea Kay, Michael Shi, Julie Chang, Paramita Sen, Jean-Charles Soria, Daniel Castellano, Andrea Harzstark, Jürgen E. Gschwend, Chia-Chi Lin, Jose A. Lopez-Martin, and Eric Angevin
- Abstract
Purpose: Signaling through the fibroblast growth factor (FGF) pathway may account for tumor resistance to antiangiogenic therapies targeting the VEGF pathway. Here, dovitinib (TKI258), a potent oral inhibitor of FGF receptor, VEGF receptor (VEGFR), and platelet-derived growth factor receptor tyrosine kinases, is studied in a dose escalation trial.Experimental Design: Patients with advanced or metastatic renal cell carcinoma (RCC) with predominant clear cell histology were treated with oral dovitinib 500 or 600 mg/day (5-days-on/2-days-off schedule).Results: Twenty heavily pretreated patients (median 3 prior regimens) were enrolled, with 16, 11, and 12 patients having previously received at least 1: VEGFR inhibitor, mTOR inhibitor, and immunotherapy, respectively. Fifteen and 5 patients were treated in 500- and 600-mg cohorts, respectively. Three patients experienced dose-limiting toxicities: grade 2 bradycardia (500 mg), grade 4 hypertensive crisis (600 mg), and grade 3 asthenia with grade 2 nausea and vomiting (600 mg). The most common adverse events related to dovitinib were nausea (75%), diarrhea (70%), vomiting (70%), and asthenia (50%), the majority of which were mild (grade 1 or 2), with grade 3 events 5% or less (except asthenia, 15%) and only one grade 4 event (hypertensive crisis). Two patients achieved a partial response (500 mg), and 12 patients had stable disease, including 2 patients with long lasting disease stabilizations (>1 year) in the 500-mg cohort.Conclusions: Dovitinib was tolerable and showed antitumor activity at a maximum tolerated dose of 500 mg on a 5-days-on/2-days-off schedule in heavily pretreated RCC patients. Clin Cancer Res; 19(5); 1257–68. ©2012 AACR.
- Published
- 2023
- Full Text
- View/download PDF
20. Supplementary Table 2 from Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
- Author
-
Eric Angevin, Michael Shi, Matthew Squires, Nicoletta Pirotta, Sarah Beall, Andrea Harzstark, Jürgen E. Gschwend, Chia-Chi Lin, Daniel Castellano, Yen-Chuan Ou, Alain Ravaud, Viktor Grünwald, and Bernard Escudier
- Abstract
PDF file - 25KB, Supplemental Table 2 contains a summary of the newly occurring qualitative ECG abnormalities.
- Published
- 2023
- Full Text
- View/download PDF
21. Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
- Author
-
Dong-Wan Kim, Michael Shi, Fabrice Branle, Yuanbo Song, Pilar Cazorla Arratia, Felipe K. Hurtado, Pilar Garrido, Chong-Jen Yu, Mark McKeage, Margarita Majem, Rita Chiari, Sergey Orlov, Chao-Hua Chiu, Patrick Y. Wen, Heather A. Wakelee, Martin J. van den Bent, Erin M. Bertino, Fabrice Barlesi, and Laura Q.M. Chow
- Abstract
Purpose:Central nervous system metastases are a prominent cause of morbidity and mortality in patients with ALK-positive (ALK+) non–small cell lung cancer (NSCLC). The phase II ASCEND-7 (NCT02336451) study was specifically designed to assess the efficacy and safety of the ALK inhibitor (ALKi) ceritinib in patients with ALK+ NSCLC metastatic to the brain and/or leptomeninges.Patients and Methods:Patients with active brain metastases were allocated to study arms 1 to 4 based on prior exposure to an ALKi and/or prior brain radiation (arm 1: prior radiotherapy/ALKi-pretreated; arm 2: no radiotherapy/ALKi-pretreated; arm 3: prior radiotherapy/ALKi-naïve; arm 4: no radiotherapy/ALKi-naïve). Arm 5 included patients with leptomeningeal carcinomatosis. Patients received ceritinib 750 mg once daily (fasted condition). Primary endpoint was investigator-assessed whole-body overall response rate (ORR) per RECIST v1.1. Secondary endpoints included disease control rate (DCR) and intracranial/extracranial responses.Results:Per investigator assessment, in arms 1 (n = 42), 2 (n = 40), 3 (n = 12), and 4 (n = 44), respectively: whole-body ORRs [95% confidence interval (CI)] were 35.7% (21.6–52.0), 30.0% (16.6–46.5), 50.0% (21.1–78.9), and 59.1% (43.2–73.7); whole-body DCR (95% CI): 66.7% (50.5–80.4), 82.5% (67.2–92.7), 66.7% (34.9–90.1), and 70.5% (54.8–83.2); intracranial ORRs (95% CI): 39.3% (21.5–59.4), 27.6% (12.7–47.2), 28.6% (3.7–71.0), and 51.5% (33.5–69.2). In arm 5 (n = 18), whole-body ORR was 16.7% (95% CI, 3.6–41.4) and DCR was 66.7% (95% CI, 41.0–86.7). Paired cerebrospinal fluid and plasma sampling revealed that ceritinib penetrated the human blood–brain barrier.Conclusions:Ceritinib showed antitumor activity in patients with ALK+ NSCLC with active brain metastases and/or leptomeningeal disease, and could be considered in the management of intracranial disease.See related commentary by Murciano-Goroff et al., p. 2477
- Published
- 2023
- Full Text
- View/download PDF
22. 105 Prevalence of claudin18.2 and PD-L1 expression in chinese gastric/gastroesophageal junction adenocarcinoma
- Author
-
Linlin Mao, Wei Yi, Xu-Alan Lin, Ying Gu, Zhenzhong Xia, Chuan Qi, Michael Shi, Steven Yu, and Xueming Qian
- Published
- 2022
- Full Text
- View/download PDF
23. 771 A phase 1, first in human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors
- Author
-
Lei Chen, Anthony Tolcher, Nashat Gabrail, Minal Barve, Xiaohua WU, Jian Zhang, Michael Shi, Chuan Qi, Steven Yu, Jenny Yao, Jianming Wang, and Christopher Cavanaugh
- Published
- 2022
- Full Text
- View/download PDF
24. Abstract CT225: Surufatinib plus toripalimab for first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 positive expression: A multicenter, single-arm phase 2 study
- Author
-
Ying Cheng, Lin Shen, Zhendong Chen, Feng Ye, Xianjun Yu, Xing Zhang, Dongmei Ji, Baorui Liu, Lijie Song, Chunjiao Wu, Ming Lu, Wei Chen, Jingxun Wu, Heli Gao, Desheng Weng, Weina Shen, Rutian Li, Minjie Yang, Jinghong Zhou, Haiyan Shi, Panfeng Tan, Songhua Fan, Michael Shi, and Weiguo Su
- Subjects
Cancer Research ,Oncology - Abstract
Background: Surufatinib (S, a small-molecule inhibitor of VEGFR 1-3, FGFR1 and CSF-1R) plus toripalimab (T, an anti-PD-1 antibody) showed encouraging antitumor activity in solid tumors (Cao YS, 2022). Programmed death ligand 1 (PD-L1) expression is the established biomarker for 1L immune checkpoint inhibitors therapy in advanced NSCLC. We conducted an open-label, multi-cohort, single-arm phase 2 study to evaluate the safety and efficacy of S+T in patients (pts) with advanced solid tumors. Here, we reported the results of advanced NSCLC with PD-L1 positive expression cohort. Methods: Eligible pts had histologically confirmed advanced NSCLC with no prior systemic chemotherapy, PD-L1 positive (defined as PD-L1 TPS expression ≥1% [sp263]), and without EGFR, ALK or ROS1 genetic alteration if non-sq-NSCLC. Enrolled pts received 21-day cycles of S (250 mg orally QD) plus T (240 mg IV, Q3W) until disease progression or intolerable toxicity or the maximum duration of treatment with toripalimab is 24 months. The primary endpoint was objective response rate (ORR) per RECIST 1.1. Results: From July 2020 to September 2021, 55 pts were screened, of whom 23 pts were enrolled and received the treatment of S+T. Median age was 66 years (range: 49-73), 16 (69.6%) were male and 12 (52.2%) had squamous histology. Pts with PD-L1 TPS ≥50% and Conclusion: Surufatinib and toripalimab combination showed a promising antitumor activity in 1L therapy for advanced PD-L1 positive NSCLC with manageable toxicity. This study might represent a potential treatment option for these pts. Clinical trial information: NCT04169672. Citation Format: Ying Cheng, Lin Shen, Zhendong Chen, Feng Ye, Xianjun Yu, Xing Zhang, Dongmei Ji, Baorui Liu, Lijie Song, Chunjiao Wu, Ming Lu, Wei Chen, Jingxun Wu, Heli Gao, Desheng Weng, Weina Shen, Rutian Li, Minjie Yang, Jinghong Zhou, Haiyan Shi, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su. Surufatinib plus toripalimab for first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 positive expression: A multicenter, single-arm phase 2 study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT225.
- Published
- 2023
- Full Text
- View/download PDF
25. Abstract 4020: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies
- Author
-
Linfang Wang, Junqing Liang, Zhihu Gao, Jia Hu, Weigang He, Xianwen Yang, Fangfang Mao, Wei Zhang, Ying Yu, Qihang Zhang, Na Yang, Chun Zhang, Jian Wang, Yu Cai, Xiong Li, Weiguo Qing, Guangxiu Dai, Yongxin Ren, Michael Shi, and Weiguo Su
- Subjects
Cancer Research ,Oncology - Abstract
Introduction: Bruton’s tyrosine kinase (BTK), a member of the Tec family, plays a crucial role in signaling through B-cell receptor (BCR). BTK inhibition blocks BCR signals and prevents B-cell activation and growth. First-generation BTK inhibitors such as ibrutinib covalently binds to a cysteine residue (C481) of BTK. Their most frequent acquired resistance is the development of a serine mutation in the binding site (C481S). Next generation BTK inhibitors such as LOXO-305 and ARQ 531 are being developed to overcome this resistance to first-generation inhibitors. Methods: HMPL-760 was tested in biochemical assays using recombinant human wild type (WT) and C481S mutant BTKs. Its selectivity was carried out using Eurofins Cerep KinaseProfilerTM panel. Cellular activity of HMPL-760 was evaluated in HEK293 cells stably transfected with BTKWT or BTKC481S, and other tumor cell lines, which are either human diffuse large B cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) cell lines. The in vivo antitumor activity and PKPD correlation of HMPL-760 was studied in HBL-1 xenograft mouse models bearing BTKWT or BTKC481S respectively. Results: In biochemical assays, HMPL-760 strongly inhibits BTK kinase activities towards wild-type BTK (BTKWT) and C481S mutant (BTKC481S), and binds to BTK in a reversible way. HMPL-760 demonstrates high selectivity in a panel containing 413 kinases. In cellular assays, HMPL-760 displays strong anti-proliferative activities in B-cell lymphoma cells (TMD-8, OCI-LY10, REC-1, HBL-1 and HBL-1-BTKC481S) harboring either BTKWT or BTKC481S (GI50: 0.0015-0.046 μM). In human whole blood assay, HMPL-760 inhibits activation of B-cells at nanomolar concentrations measured by inhibition of immunoglobulin-induced CD69 expression in CD19+cells. HMPL-760 shows ≥ 10-fold inhibitory potency than ARQ 531 in both BTKWT and BTKC481S cells, and ~3-fold higher inhibitory potency than that of LOXO-305 in BTKC481S cells. In cellular assay by detecting p-BTK after compound washout, HMPL-760 maintains a longer duration of target inhibition than LOXO-305 in both BTK wild type (HBL-1) and BTK mutant (HBL-1-BTKC481S) cell lines. HMPL-760 displays dose-dependent antitumor efficacy in multiple human B cell lymphoma xenograft models in mice when orally administered at 3~50 mg/kg once daily. Complete tumor regression occurs in most of the tested models at the high dose levels. HMPL-760 shows much stronger antitumor efficacy than LOXO-305 and ARQ 531 at similar dose level, which may be associated with HMPL-760’s higher drug exposures and more sustainable inhibition on BTK phosphorylation in the tumor tissues. Conclusion: HMPL-760 is a reversible, selective, highly potent, BTK inhibitor targeting both BTKWT and BTKC481S. The first-in-human Phase 1 clinical trials of HMPL-760 are under way in patients with r/r B-NHL (NCT05190068, NCT05176691). Citation Format: Linfang Wang, Junqing Liang, Zhihu Gao, Jia Hu, Weigang He, Xianwen Yang, Fangfang Mao, Wei Zhang, Ying Yu, Qihang Zhang, Na Yang, Chun Zhang, Jian Wang, Yu Cai, Xiong Li, Weiguo Qing, Guangxiu Dai, Yongxin Ren, Michael Shi, Weiguo Su. HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4020.
- Published
- 2023
- Full Text
- View/download PDF
26. Using a collaborative learning health system approach to improve disease activity outcomes in children with juvenile idiopathic arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
- Author
-
Julia G. Harris, Catherine A. Bingham, Sheetal S. Vora, Cagri Yildirim-Toruner, Michelle Batthish, Danielle R. Bullock, Jon M. Burnham, Danielle C. Fair, Kerry Ferraro, Suhas Ganguli, Mileka Gilbert, Beth S. Gottlieb, Olha Halyabar, Melissa M. Hazen, Ronald M. Laxer, Tzielan C. Lee, Alice Liu, Daniel J. Lovell, Melissa L. Mannion, Edward J. Oberle, Nancy Pan, Michael Shishov, Jennifer E. Weiss, and Esi M. Morgan
- Subjects
juvenile arthritis ,quality improvement ,outcome measures ,pediatrics ,rheumatology ,registries ,Pediatrics ,RJ1-570 - Abstract
IntroductionThe Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a North American learning health network focused on improving outcomes of children with juvenile idiopathic arthritis (JIA). JIA is a chronic autoimmune disease that can lead to morbidity related to persistent joint and ocular inflammation. PR-COIN has a shared patient registry that tracks twenty quality measures including ten outcome measures of which six are related to disease activity. The network's global aim, set in 2021, was to increase the percent of patients with oligoarticular or polyarticular JIA that had an inactive or low disease activity state from 76% to 80% by the end of 2023.MethodsTwenty-three hospitals participate in PR-COIN, with over 7,200 active patients with JIA. The disease activity outcome measures include active joint count, physician global assessment of disease activity, and measures related to validated composite disease activity scoring systems including inactive or low disease activity by the 10-joint clinical Juvenile Arthritis Disease Activity Score (cJADAS10), inactive or low disease activity by cJADAS10 at 6 months post-diagnosis, mean cJADAS10 score, and the American College of Rheumatology (ACR) provisional criteria for clinical inactive disease. Data is collated to measure network performance, which is displayed on run and control charts. Network-wide interventions have included pre-visit planning, shared decision making, self-management support, population health management, and utilizing a Treat to Target approach to care.ResultsFive outcome measures related to disease activity have demonstrated significant improvement over time. The percent of patients with inactive or low disease activity by cJADAS10 surpassed our goal with current network performance at 81%. Clinical inactive disease by ACR provisional criteria improved from 46% to 60%. The mean cJADAS10 score decreased from 4.3 to 2.6, and the mean active joint count declined from 1.5 to 0.7. Mean physician global assessment of disease activity significantly improved from 1 to 0.6.ConclusionsPR-COIN has shown significant improvement in disease activity metrics for patients with JIA. The network will continue to work on both site-specific and collaborative efforts to improve outcomes for children with JIA with attention to health equity, severity adjustment, and data quality.
- Published
- 2024
- Full Text
- View/download PDF
27. Open repair of an abdominal aortic and right common iliac artery aneurysm with idiopathic retroperitoneal fibrosis in a 19-month-old infant
- Author
-
Khalil Chamseddin, MD, Antonio Solano, MD, Melissa R. Keller, MD, Michael C. Siah, MD, Gerardo Gonzalez-Guardiola, MD, Vivek Prakash, MD, Michael Shih, MD, M. Shadman Baig, MD, Carlos H. Timaran, MD, and Melissa L. Kirkwood, MD
- Subjects
Abdominal aortic aneurysm ,Aortic disease ,Congenital ,Pediatric aneurysms ,Pediatric vascular surgery ,Surgical repair ,Surgery ,RD1-811 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
An abdominal aortic aneurysm (AAA) in children is a rare clinical condition, with idiopathic AAAs even more atypical. We report a case of a 19-month-old girl with incidental findings of an infrarenal AAA and right common iliac artery aneurysm during workup for heart failure. Extensive genetic testing was unremarkable for connective tissue disorders. An aortic bi-iliac artery bypass with a Dacron graft from the infrarenal aorta to the right external iliac artery and left common iliac artery was performed. The patient achieved complete recovery and only required one oral hypertensive medication at 30 days of follow-up. Wide patency of the graft was observed on the 3-month follow-up computed tomography angiogram.
- Published
- 2024
- Full Text
- View/download PDF
28. Service development project to pilot a digital technology innovation for video direct observation of therapy in adult patients with asthma
- Author
-
Michael Scott, Michael Shields, Rachel Huey, Glenda Fleming, James C McElnay, Katherine O’Neill, Cairine Gormley, and Martin G Kelly
- Subjects
Medicine (General) ,R5-920 - Abstract
Background Adherence to pharmacotherapy and use of the correct inhaler technique are important basic principles of asthma management. Video- or remote-direct observation of therapy (v-DOT) could be a feasible approach to facilitate monitoring and supervising therapy, supporting the delivery of standard care.Objective To explore the utility and the feasibility of v-DOT to monitor inhaler technique and adherence to treatment in adults attending the asthma outpatient service in a tertiary hospital in Northern Ireland.Method The project evaluated use of the technology with 10 asthma patients. Patient and clinician feedback was obtained, in addition to measures of patient engagement and disease-specific clinical markers to assess the feasibility and utility of v-DOT technology in this group of patients.Results The engagement rate with v-DOT for participating patients averaged 78% (actual video uploads vs expected video uploads) over a median 7 week usage period. Although 50% of patients reported a technical issue at some stage during the usage period, all patients and clinicians reported that the technology was easy to use and that they were satisfied with the outcomes. A range of positive impacts were observed, including optimised inhaler technique and an observed improvement in lung function. An increase in asthma control test scores aligned with clinical aims to promote adherence and alleviate symptoms.Conclusion The v-DOT technology was shown to be a feasible method of assessing inhaler technique and monitoring adherence in this small group of adult asthma patients. A range of positive impacts for participating patients and clinicians were observed. Not all patients invited to join the project agreed to participate or engage with using the technology, highlighting that in this setting, digital modes of delivering care provide only one of the approaches in the necessary “tool kit” for clinicians and patients.
- Published
- 2024
- Full Text
- View/download PDF
29. A phase I study to evaluate the safety, tolerability, and pharmacokinetics of MSB0254 in Chinese patients with solid tumors
- Author
-
Tianshu Liu, Yulong Zheng, Yi Feng, Yiyi Yu, Wei Li, Cheng Xiao, Jiong Qian, Chenyu Mao, Ning Li, Michael Shi, Chuan Qi, LEI Chen, Steven Yu, Jenny Yao, Lingmin Lu, and Jianming Wang
- Subjects
Cancer Research ,Oncology - Abstract
3023 Background: MSB0254 is a humanized vascular endothelial growth factor receptor 2 (VEGFR-2) monoclonal antibody. MSB0254 inhibits angiogenesis induced by either VEGF-A or –C. This trial is a phase I study to evaluate MSB0254’s safety, tolerability and PK profiles, as well as early anti-cancer activities in Chinese patients with advanced solid tumors. Methods: In this phase I study (NCT04381325), locally advanced or metastatic solid tumor patients failed previous standard treatments were enrolled. In the dose escalation phase, following 3+3 rules, MSB0254 was given intravenously Q2W (every 2 weeks) at 4mg/kg, 8mg/kg, 12mg/kg, 16mg/kg, and Q3W at 20mg/kg. In the dose expansion phase, patients with selected tumor types will be treated with MSB0254 at 16mg/kg Q2W or 20mg/kg Q3W. Primary objectives were to evaluate the safety and tolerability and to identify maximum tolerable dose (MTD) and/or Recommended Phase 2 Dose (RP2D). Secondary objectives included the assessment of pharmacokinetics, immunogenicity, and preliminary efficacy per RECIST1.1. Results: As of 10th Jan, 2022, a total of 22 Chinese patients have been enrolled into the dose escalation phase and treated with MSB0254 at different dose levels from 4-16mg/kg Q2W or 20mg/kg Q3W. MTD was not reached. One DLT was reported in 12mg/kg Q2W dose cohort. A subject with intra-cholangial carcinoma developed G3 (grade 3) upper gastrointestinal hemorrhage on the C1D13. The adverse event was resolved after symptomatic treatment. The most common treatment-emergent adverse events (TEAEs) (>10%) included: hypertension (27.3%), AST increased (27.3%), γ-GGT increased (22.7%), neutrophil count decreased (18.2%), proteinuria (18.2%), WBC count decreased (13.6%), platelet count decreased (13.6%) and anemia (13.6%). Three subjects (13.6%) experienced G3 TEAEs: 1 upper gastrointestinal hemorrhage, 1 anemia and 1 Hypertriglyceridemia. No G4/5 TEAE was observed. And three subjects (13.6%) experienced 3 SAEs: 1 upper gastrointestinal hemorrhage, 1 G2 intestinal obstruction caused hospitalization and 1 G2 fatigue caused hospitalization. MSB0254 displayed a dose proportional pharmacokinetic profile between 4-16 mg/kg Q2W with calculated T1/2 of 6-9 days. Eighteen subjects had at least one tumor assessment per RECIST 1.1 after MSB0254 treatment. Eleven subjects (61.1%) had best response of stable disease (SD). Four of them had stable disease for more than 6 months, including a neuroendocrine tumor (NET), a gastric cancer, an epithelioid hemangioendothelioma (EHE) and a submaxillary gland carcinoma patient. Conclusions: MSB0254 demonstrated a manageable safety profile and preliminary antitumor activity in patients with advanced solid tumors. 16mk/kg Q2W is recommended as RP2D. 20mg/kg Q3W is still under investigation. The study of MSB0254 on the expansion phase in selected tumor patients is ongoing. Clinical trial information: NCT04381325.
- Published
- 2022
- Full Text
- View/download PDF
30. Screening for juvenile idiopathic arthritis associated uveitis with laser flare photometry in the pediatric rheumatology office: a prospective observational study
- Author
-
Kaleo Ede, Michael Shishov, Elisa Wershba, Nikita Goswami, Sabrina Gorry, Malin Joseph, Lucia Mirea, and James O’Neil
- Subjects
Juvenile idiopathic arthritis asociated Uveitis ,Laser flare photometry ,Screening ,Diagnosis ,Pediatrics ,RJ1-570 ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background Juvenile Idiopathic Arthritis (JIA) Associated Uveitis (JIA-U) remains one of the most serious complications of JIA in children. Historically, pediatric JIA is diagnosed by an Optometrist or Ophthalmologist; however, barriers to scheduling increase wait times that may delay diagnosis and treatment. The purpose of this study was to evaluate laser flare photometry (LFP) use to diagnose JIA-U in the Pediatric Rheumatology clinic for patients with JIA. Methods This prospective, observational study assessed pediatric patients diagnosed with JIA without a previous history of uveitis between January 2020 and September 2022. All patients underwent at least one evaluation of both eyes using a Kowa FM-600 laser flare photometer during a routine Rheumatology appointment, as well as a standard slit lamp examination (SLE) by optometry or ophthalmology during routine clinical care. Data collected at patient visits included demographics, JIA characteristics, treatment, LFP readings, and anterior chamber (AC) cell grade score utilizing the SUN grading system. Data were summarized using descriptive analyses and the uveitis false positive rate was calculated. Results The study cohort included 58 pediatric patients diagnosed with JIA. The mean age was 8.4 years (1.2–16.3 years) at diagnosis and 11.9 (4.8–16.5 years) at enrollment. The mean duration of disease at time of enrollment was 42 months (range; 0-157 months). Participants were predominantly female (n = 43, 74.1%) and white/Caucasian race (n = 37, 63.8%). The most common JIA subtypes included persistent oligoarticular JIA (n = 19, 32.8%), and RF negative polyarticular JIA (n = 12, 20.7%). There were 12 ANA positive patients (20.7%). At enrollment, 16 patients (27.6%) were not on medications, with 20 (34.5%) on methotrexate, 20 (34.5%) on adalimumab, 6 (10.3%) on tocilizumab, and 5 (8.6%) on etanercept. During the study period, no eye exams detected active uveitis based on SLE with a SUN grade over 0. However, of the 135 LFP readings, 131 (97.0%) were normal, yielding a false positive rate of 3% (95% CI: 0.8%, 7.4%). Conclusions LFP is a non-invasive tool that can be utilized in the pediatric rheumatology clinic to evaluate for JIA-U. There is a low false positive rate of LFP when compared with standard slit lamp exam.
- Published
- 2024
- Full Text
- View/download PDF
31. A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors
- Author
-
Nashat Y. Gabrail, Anthony Tolcher, Olatunji B. Alese, Michael Cecchini, Patel Manish, Haeseong Park, Jordan Berlin, Erika P. Hamilton, Yingjie Huang, Lingmin Lu, Jianming Wang, Michael Shi, and Ming F. Tong
- Subjects
Cancer Research ,Oncology - Abstract
TPS375 Background: In normal conditions, Claudin (CLDN)18.2 is a tight junction protein with expression strictly confined to differentiated epithelial cells in gastric mucosa. CLDN18.2 has been found to be upregulated, and involved in tumor development and progression in a variety of tumor types such as gastric, pancreatic, and bile duct cancer (BTC). The biological characteristics of CLDN18.2 suggest it is an ideal therapeutic target for cancer drug development. IMAB362 is the first anti-CLDN18.2 monoclonal antibody (mAb) of high potency to have been tested in humans and it revealed clinical efficacy in gastric cancer in a phase II study. TST001, a humanized IgG1 mAb, binds to a distinct epitope of CLDN18.2 with higher affinity and mediates CLDN18.2 expressing cancer cell death through antibody-dependent cellular cytotoxicity (ADCC) in comparison with IMAB362; Furthermore, TST001 is produced using an optimized glycoengineering process to increase affinity to FcR. The enhanced binding to CLDN18.2 on tumor cells and FcR on NK cells results in more efficient engagement of the tumor cells with NK cells and antibody mediated cellular cytotoxicity. In preclinical xenograft studies, TST001 displayed potent anti-tumor activities in the tumor models with medium to high level of CLDN18.2 expression and synergy anti-cancer effect with checkpoint inhibitor. A mAb specific for CLDN18.2 was also developed as an IHC based biomarker for patient enrollment in the clinical trials. Methods: This is an open-label, multi-center, phase I clinical trial to evaluate the safety, maximum tolerated dose (MTD), pharmacokinetics (PK) profile and preliminary anti-cancer effect of TST001 in patients with locally advanced or metastatic solid tumors. (NCT04396821) The study consists of two parts: Part A is a 3+3 dose escalation design with sequential dose cohorts of 1, 3, 6, 10mg/kg in Q2W and Q3W schedules. Based on the emerging safety data, higher doses may be proposed for testing. About 27-54 patients will be enrolled. Dose expansion (Part B) will utilize doses of TST001 based on the emerging data from Part A. In Part B, up to 20 patients with CLDN18.2 overexpression per tumor specific cohort will be enrolled to 3 cohorts: A: TST001 single agent in gastric/gastroesophageal junction (G/GEJ) cancer; B: TST001 + nivolumab in G/GEJ cancer; C: TST001 single agent in pancreatic cancer or BTC. All patients in Part B will be selected by CLDN18.2 expression by central lab testing. The safety, anti-tumor activity, and PK will be further assessed in Part B. Enrolment began in July 2020 in the USA and is ongoing in multiple sites. As of 20 September, 2021, 23 subjects were dosed in Part A and the dose of 10mg/kg is being tested. Another phase I study of TST001 single agent and in combination with chemotherapy in patients with metastatic solid tumor is also ongoing in China (NCT04495296).
- Published
- 2022
- Full Text
- View/download PDF
32. RevCore thrombectomy system for treatment of chronic left external and common iliac vein stent occlusion
- Author
-
Antonio Solano, MD, Andrea Klein, MD, Gerardo Gonzalez-Guardiola, MD, Khalil Chamseddin, MD, Vivek Prakash, MD, Michael Shih, MD, M. Shadman Baig, MD, Carlos H. Timaran, MD, Melissa L. Kirkwood, MD, and Michael C. Siah, MD
- Subjects
Deep venous stenting ,Deep venous thrombosis ,Iliocaval reconstruction ,Inferior vena cava ,Inferior vena cava atresia ,In-stent thrombosis ,Surgery ,RD1-811 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
In recent years, deep venous stenting has increasingly become a treatment strategy for post-thrombotic syndrome. Stent thrombosis can occur, resulting in symptom recurrence despite medical therapy, and there are few options available for durable stent patency restoration. We present a case of a 50-year-old male with prior iliocaval reconstruction that experienced recurrent left lower extremity swelling secondary to occlusion of left external iliac and common iliac vein stents during follow-up. Mechanical thrombectomy with the RevCore System and angioplasty was performed. One month later, the patient demonstrated widely patent bilateral iliac vein stents and complete symptomatic resolution. The RevCore System is a feasible alternative for treatment of chronic in-stent thrombosis.
- Published
- 2024
- Full Text
- View/download PDF
33. Mangrove peat and algae leachates elicit rapid and contrasting molecular and microbial responses in coastal waters
- Author
-
Elise S. Morrison, Yina Liu, Albert Rivas-Ubach, João Henrique Fernandes Amaral, Michael Shields, Todd Z. Osborne, Rosalie Chu, Nicholas Ward, and Thomas S. Bianchi
- Subjects
Geology ,QE1-996.5 ,Environmental sciences ,GE1-350 - Abstract
Abstract As sea level rises, previously sequestered blue carbon can be exported offshore as particulate or dissolved organic matter where it may be re-mineralized or sequestered. The priming effect, or interactive effects of organic matter turnover with a mixed substrate, is well described in soils, but still debated in aquatic systems. Priming may contribute to enhanced blue carbon re-mineralization in coastal environments. Here we examined mangrove-derived dissolved organic matter turnover in a lab incubation, with leachates from mangrove peat, 13C-labeled algae, and peat+algae (primed). Particulate and dissolved organic matter were assessed; microbial metatranscriptomes were evaluated; and dissolved organic matter was characterized with high resolution mass spectrometry. Stable isotopes indicated rapid allocation of algal-derived dissolved organic matter into particulate organic matter. The algal treatment had the greatest increase in carbon dioxide, but primed and peat treatments had the greatest loss of dissolved organic carbon, greater RNA concentrations, and similar changes in total carbon dioxide. This suggests that, while total carbon dioxide did not increase under priming conditions, the addition of a peat substrate may promote microbial biomass production relative to carbon dioxide production. This work highlights that more targeted studies investigating the specific mechanisms of priming are necessary to address the molecular and microbial transformations associated with priming in aquatic systems.
- Published
- 2023
- Full Text
- View/download PDF
34. Is there any truth in the myth that IVF treatments involve weight gain?
- Author
-
Bozhena Saar-Ryss, Michael Shilo, Michael Friger, Leonti Grin, Yulia Michailov, Simion Meltcer, Svetlana Zaks, Jacob Rabinson, Tal Lazer, and Shevach Friedler
- Subjects
IVF ,antagonist protocol ,weight gain ,weight change ,COH ,Reproduction ,QH471-489 ,Medicine (General) ,R5-920 - Abstract
PurposeTo examine body weight change in women undergoing in vitro fertilization and embryo transfer (IVF-ET) using antagonist protocol after up to three treatment cycles.MethodsA prospective cohort study among IVF patients treated between 2018 and 2019. Each patient underwent weight measurement three times during the treatment cycle: before treatment, at the beginning of the hormonal stimulation, and at the completion of the cycle, on the day of the pregnancy test. Data were also analyzed according to the body mass index (BMI) groups for normal weight, overweight, and obese patients. Finally, weight changes were recorded following altogether 519 treatment cycles, 240, 131, and 148 cycles, for normal weight, overweight, and obese patients, respectively.ResultsThe change in the patient's weight was clinically non-significant either during the waiting period or during gonadotropin administration, and overall, during the first, second, or third treatment cycles. The recorded mean total weight change of 0.26 ± 1.85, 0.4 ± 1.81, and 0.17 ± 1.7, after the first, second, or third treatment cycles, represent a change of 0.36%, 0.56%, and 0.23% of their initial weights, respectively. This change of less than 1% of the body weight falls short of the clinically significant weight gain of 5%–7%. Analyzing the data for the various BMI groups, the changes observed in body weight were under 1%, hence with no clinical significance.ConclusionThe findings of the study reject the myth that hormone therapy involves clinically significant weight gain, and this can lower the concerns of many patients who are candidates for treatment of assisted reproductive technology.
- Published
- 2024
- Full Text
- View/download PDF
35. Ventricular tachycardia in the setting of a large cardiac fibroma in a pediatric patient
- Author
-
Jennifer O'Neal, Sunita Ferns, Weston G. Andrews, and Michael Shillingford
- Subjects
Ventricular tachycardia ,Cardiac tumor ,Fibroma ,SARS CoV2 ,Pediatric ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Ventricular tachycardia and cardiac tumors are both extremely rare diagnoses in pediatric patients. We report a pediatric case of cardiac fibroma that was noted during the work up of ventricular tachycardia in a young patient concomitantly diagnosed with severe acute respiratory syndrome coronavirus 2.
- Published
- 2023
- Full Text
- View/download PDF
36. Acute limb ischemia secondary to bullet embolism following a cardiac gunshot wound in a pediatric patient
- Author
-
Eliza Ferrari, MD, Tiffany Guard, MS, Vivek Prakash, MD, Michael Shih, MD, Melissa Kirkwood, MD, and Michael Siah, MD
- Subjects
Acute limb ischemia ,BB gun ,Bullet embolism ,Cardiac trauma ,Gunshot wound ,Missile embolism ,Surgery ,RD1-811 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Bullet embolism following a gunshot wound to the heart is a very unusual cause of acute limb ischemia. We report the case of a 3-year-old boy who sustained a penetrating cardiac trauma secondary to an accidental self-inflicted gunshot wound with a BB (ball bearing) gun. The BB pellet entered the left ventricle and embolized into the peripheral circulation, lodging at the bifurcation of the left common femoral artery. This resulted in acute left lower extremity ischemia. The patient was successfully treated by open common femoral artery exploration and foreign body removal.
- Published
- 2023
- Full Text
- View/download PDF
37. P471: POLO-LIKE KINASE 4 INHIBITION INDUCED ANTI-LEUKAEMIC EFFECTS THROUGH HISTONE MODIFICATION IN TP53 MUTATED ACUTE MYELOID LEUKAEMIA
- Author
-
Wing Lam, Kenny Dang, Cheuk Him Man, Xiao-Yuan Zeng, Lichuan Zheng, Nelson Ka-Lam Ng, Koon-Chuen Chan, Tsz-Ho Kwok, Timothy Chi-Chun Ng, Wing-Yan Leung, Michael Shing-Yan Huen, Carmen Chak-Lui Wong, Chi Wai Eric So, Zhixun Dou, Mark Robert Bray, Tak Mak, and Anskar Yh Leung
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
38. Q Fever infection after endovascular aortic bi-iliac aneurysm repair with endograft
- Author
-
Antonio Solano, Melissa R. Keller, Alejandro Pizano, M. Shadman Baig, Michael Siah, Vivek Prakash, Khalil Chamseddin, Melissa L. Kirkwood, and Michael Shih
- Subjects
Coxiella burnetii ,Q fever ,Vascular graft ,Endovascular aortic repair ,Aortic aneurysm ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Surgery ,RD1-811 - Abstract
Background: Q fever is a zoonotic disease produced by infection with Coxiella burnetii which can cause cardiovascular complications such as endocarditis, aneurysms, and vascular graft infections but is uncommon in the absence of exposure to animal reservoirs. Case summary: We present a case of a 64-year-old patient with chronic Q fever infection of an aortic endograft resulting in aorto-enteric fistula. Exposure history reported a recent travel to Mexico and no contact with animals during the stay. Vascular endograft explant was performed and intraoperative findings revealed an abscess cavity along the right anterior abdominal aorta and an aorto-enteric fistula. Extended course doxycycline and hydroxychloroquine were initiated. Due to the diagnostic challenge, we focused on preventing sepsis progression and exposure mitigation to the surgical team. Conclusion: We highlight the atypical presentation of a Q fever aneurysm, outcomes and possible delayed sequelae. A timely diagnosis and high clinical suspicion are paramount to reduce morbidity rate.
- Published
- 2023
- Full Text
- View/download PDF
39. Endovascular reconstruction of aortic bifurcation for aortic pseudoaneurysm in a pediatric trauma patient
- Author
-
K. Benjamin Lee, MD, Antonio Solano, MD, M. Shadman Baig, MD, Gerardo Gonzalez-Guardiola, MD, Carlos H. Timaran, MD, Melissa R. Keller, MD, Melissa L. Kirkwood, MD, and Michael Shih, MD
- Subjects
Aorta ,Endovascular therapies ,Pediatric vascular surgery ,Pseudoaneurysm ,Trauma ,Surgery ,RD1-811 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Endovascular treatment options for vascular injury in pediatric patients are quite limited owing to concerns regarding long-term durability and the lack of devices suitable for the pediatric anatomy. However, in rare circumstances, open surgical therapy will not be an option, and patients will require unconventional endovascular solutions for lifesaving or limb-saving therapies. In the present report, we describe an endovascular treatment of a pediatric patient for whom initial surgical management of a blunt abdominal aortic injury had failed, with subsequent development of an aortic pseudoaneurysm. A 10-year-old girl had presented after a high-speed motor vehicle accident with a seatbelt sign. Multiple abdominal injuries were identified, including blunt aortic injury, significant devitalization of the small bowel, colonic perforation with fecal contamination, multiple lumbar spine fractures, and pulmonary contusions. The patient developed bilateral lower extremity ischemia from the aortic injury and had initially undergone open repair. One month later, the patient had developed a pseudoaneurysm of the aorta near the aortic bifurcation. Because of the hostile abdomen and ensuing short gut syndrome, the pseudoaneurysm was managed using endovascular techniques. The limb of an Excluder internal iliac branch endoprosthesis (W.L. Gore & Associates, Flagstaff, AZ) was used as the endograft. The aortic bifurcation was raised and reconstructed using four Viabahn self-expanding stents (W.L. Gore & Associates). The completion angiogram showed complete resolution of the pseudoaneurysm. The follow-up computed tomography angiogram showed widely patent stent grafts with complete resolution of the pseudoaneurysm. Endovascular management of traumatic vascular injuries in pediatric patients is feasible. The likelihood of reintervention in the future is high with patient growth. However, it is a viable option in lifesaving or limb-saving situations in which open repair is high risk.
- Published
- 2023
- Full Text
- View/download PDF
40. A multisource database tracking the impact of the COVID-19 pandemic on the communities of Boston, MA, USA
- Author
-
Alina Ristea, Riley Tucker, Shunan You, Mehrnaz Amiri, Nicholas Beauchamp, Edgar Castro, Qiliang Chen, Alexandra Ciomek, Bidisha Das, Justin de Benedictis-Kessner, Sage Gibbons, Forrest Hangen, Barrett Montgomery, Petros Papadopoulos, Cordula Robinson, Saina Sheini, Michael Shields, Xin Shu, Michael Wood, Babak Heydari, and Dan O’Brien
- Subjects
Science - Abstract
Measurement(s) Neighborhood context Technology Type(s) Naturally-occurring data Sample Characteristic - Environment City neighborhoods Sample Characteristic - Location Boston, MA, USA
- Published
- 2022
- Full Text
- View/download PDF
41. Considering potential benefits, as well as harms, from the COVID-19 disruption to cancer screening and other healthcare services
- Author
-
Katy JL Bell, Fiona F Stanaway, Kirsten McCaffery, Michael Shirley, and Stacy M Carter
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Since 2020, hundreds of thousands of more deaths than expected have been observed across the globe. Amid the coronavirus 2019 (COVID-19) pandemic, current research priorities are to control the spread of infection and minimise loss of life. However, there may be future opportunities to learn from the pandemic to build a better healthcare system that delivers maximum health benefits with minimum harm. So far, much research has focused on foregone benefits of healthcare services such as cancer screening during the pandemic. A more balanced approach is to recognise that all healthcare services have potential harms as well as benefits. In this way, we may be able to use pandemic ‘natural experiments’ to identify cases where a reduction in a healthcare service has not been harmful to the population and some instances where this may have even been beneficial.
- Published
- 2023
- Full Text
- View/download PDF
42. Endovascular repair of traumatic axillary artery transection associated with scapulothoracic dissociation complicated by stent separation
- Author
-
Michael Shih, MD, K. Benjamin Lee, MD, Mirza S. Baig, MD, Andrea Klein, MD, Alejandra Rodriguez, MD, and Melissa Kirkwood, MD
- Subjects
Arterial trauma ,Axillary artery injury ,Axillosubclavian artery injury ,Endovascular repair ,Scapulothoracic dissociation ,Surgery ,RD1-811 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
We report the case of a 23-year-old female pedestrian who had been struck by a car and had presented with axillary artery transection in the setting of scapulothoracic dissociation. The initial endovascular repair was compromised by her shoulder instability and had required the addition of bridging stent placement. Caution is advised with endovascular repair in this clinical scenario because of possible stent separation.
- Published
- 2023
- Full Text
- View/download PDF
43. Exploring Teslasuit’s Potential in Detecting Sequential Slip-Induced Kinematic Changes among Healthy Young Adults
- Author
-
Jacob Hepp, Michael Shiraishi, Michelle Tran, Emmy Henson, Mira Ananthanarayanan, and Rahul Soangra
- Subjects
perturbation training ,fall risk ,gait kinematics ,wearable technologies ,Chemical technology ,TP1-1185 - Abstract
This study aimed to assess whether the Teslasuit, a wearable motion-sensing technology, could detect subtle changes in gait following slip perturbations comparable to an infrared motion capture system. A total of 12 participants wore Teslasuits equipped with inertial measurement units (IMUs) and reflective markers. The experiments were conducted using the Motek GRAIL system, which allowed for accurate timing of slip perturbations during heel strikes. The data from Teslasuit and camera systems were analyzed using statistical parameter mapping (SPM) to compare gait patterns from the two systems and before and after slip. We found significant changes in ankle angles and moments before and after slip perturbations. We also found that step width significantly increased after slip perturbations (p = 0.03) and total double support time significantly decreased after slip (p = 0.01). However, we found that initial double support time significantly increased after slip (p = 0.01). However, there were no significant differences observed between the Teslasuit and motion capture systems in terms of kinematic curves for ankle, knee, and hip movements. The Teslasuit showed promise as an alternative to camera-based motion capture systems for assessing ankle, knee, and hip kinematics during slips. However, some limitations were noted, including kinematics magnitude differences between the two systems. The findings of this study contribute to the understanding of gait adaptations due to sequential slips and potential use of Teslasuit for fall prevention strategies, such as perturbation training.
- Published
- 2023
- Full Text
- View/download PDF
44. Long-term spill-over impact of COVID-19 on health and healthcare of people with non-communicable diseases: a study protocol for a population-based cohort and health economic study
- Author
-
Ian Chi Kei Wong, Chak Sing Lau, Mary Sau Man Ip, Esther Yee Tak Yu, Cindy Lo Kuen Lam, Eric Yuk Fai Wan, Kui Kai Lau, Sydney Chi Wai Tang, David Vai Kiong Chao, Karen Ann Grépin, Hin Moi Youn, Welchie Wai Kit Ko, Jianchao Quan, Ivy Lynn Mak, Michael Shing Fung Lee, and Carmen S Ng
- Subjects
Medicine - Abstract
Introduction The COVID-19 pandemic has a significant spill-over effect on people with non-communicable diseases (NCDs) over the long term, beyond the direct effect of COVID-19 infection. Evaluating changes in health outcomes, health service use and costs can provide evidence to optimise care for people with NCDs during and after the pandemic, and to better prepare outbreak responses in the future.Methods and analysis This is a population-based cohort study using electronic health records of the Hong Kong Hospital Authority (HA) CMS, economic modelling and serial cross-sectional surveys on health service use. This study includes people aged ≥18 years who have a documented diagnosis of diabetes mellitus, hypertension, cardiovascular disease, cancer, chronic respiratory disease or chronic kidney disease with at least one attendance at the HA hospital or clinic between 1 January 2010 and 31 December 2019, and without COVID-19 infection. Changes in all-cause mortality, disease-specific outcomes, and health services use rates and costs will be assessed between pre-COVID-19 and-post-COVID-19 pandemic or during each wave using an interrupted time series analysis. The long-term health economic impact of healthcare disruptions during the COVID-19 pandemic will be studied using microsimulation modelling. Multivariable Cox proportional hazards regression and Poisson/negative binomial regression will be used to evaluate the effect of different modes of supplementary care on health outcomes.Ethics and dissemination The study was approved by the institutional review board of the University of Hong Kong, the HA Hong Kong West Cluster (reference number UW 21–297). The study findings will be disseminated through peer-reviewed publications and international conferences.
- Published
- 2022
- Full Text
- View/download PDF
45. Restoring ornithine transcarbamylase (OTC) activity in an OTC‐deficient mouse model using LUNAR‐OTC mRNA
- Author
-
Hailong Yu, Edward Brewer, Michael Shields, Michael Crowder, Cristiano Sacchetti, Benchawanna Soontornniyomkij, Dandan Dou, Brenda Clemente, Marciano Sablad, Padmanabh Chivukula, Steve Hughes, Scott Roberts, Kumar Rajappan, Steve Tannis, Rose Sekulovich, Suezanne Parker, and Pattraranee Limphong
- Subjects
liver biopsy ,LUNAR‐OTC ,ornithine transcarbamylase (OTC) ,OTC activity assay ,ornithine transcarbamylase deficiency (OTCD) ,plasma ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Abstract Ornithine transcarbamylase (OTC) catalyses the reaction from ornithine to citrulline in the urea cycle. Ornithine transcarbamylase deficiency (OTCD) results in episodes of hyperammonemia. Arcturus Therapeutics developed a lipid nanoparticle (LNP)‐encapsulated OTC‐mRNA (LUNAR‐OTC) that results in a replacement enzyme and is currently undergoing clinical trials. In this study, the efficacy of LUNAR OTC‐mRNA drug in the spfash mouse model was examined by measuring the OTC enzyme activity and protein expression in the liver and plasma of OTC‐mRNA‐treated mice. Using purified citrulline‐D4 as the substrate improved the sensitivity of the OTC activity assay and allowed us to quantify the ornithine‐D4 product from the mouse plasma samples. OTC activity in the liver showed a clear dose response: The lowest dose, 0.3 mg/kg, resulted in higher activity than that of the untreated group, and the highest dose, 3 mg/kg, resulted in completely restored OTC activity in the liver. OTC activity in plasma was also dose‐dependent. A clear positive correlation between the OTC activity in the liver and that in the plasma suggests that the plasma OTC activity assay may serve as a surrogate for measuring OTC activity in liver biopsy samples. In addition, the OTC protein expression levels correlated well with the OTC activity in liver samples, but there was no quantifiable OTC protein in the plasma samples. This finding suggests that the sensitivity of the OTC activity assay is superior to that of the protein expression assay. Overall, the results of this study suggest that the OTC activity assay described here can be used as a clinical pharmacodynamic endpoint to measure the effectiveness of OTCD treatment.
- Published
- 2022
- Full Text
- View/download PDF
46. Reliability and Validity of Inertial Sensor Assisted Reaction Time Measurement Tools among Healthy Young Adults
- Author
-
Brent Harper, Michael Shiraishi, and Rahul Soangra
- Subjects
reaction time (RT) ,wearable sensors ,dual tasking ,Chemical technology ,TP1-1185 - Abstract
The assessment of movement reaction time (RT) as a sideline assessment is a valuable biomarker for mild TBI or concussion. However, such assessments require controlled laboratory environments, which may not be feasible for sideline testing during a game. Body-worn wearable devices are advantageous as being cost-effective, easy to don and use, wirelessly transmit data, and ensure unhindered movement performance. This study aimed to develop a Drop-stick Test System (DTS) with a wireless inertial sensor and confirm its reliability for different standing conditions (Foam versus No Foam) and task types (Single versus Dual), and postures (Standing versus sitting). Fourteen healthy young participants (seven females, seven males; age 24.7 ± 2.6 years) participated in this study. The participants were asked to catch a falling stick attached to the sensor during a drop test. Reaction Times (RTs) were calculated from data for each trial from DTS and laboratory camera system (gold standard). Intraclass correlation coefficients (ICC 3,k) were computed to determine inter-instrument reliability. The RT measurements from participants using the camera system and sensor-based DTS showed moderate to good inter-instrument reliability with an overall ICC of 0.82 (95% CI 0.78–0.85). Bland–Altman plots and 95% levels of agreement revealed a bias where the DTS underestimated RT by approximately 50 ms.
- Published
- 2022
- Full Text
- View/download PDF
47. Kinematic Analysis of 360° Turning in Stroke Survivors Using Wearable Motion Sensors
- Author
-
Masoud Abdollahi, Pranav Madhav Kuber, Michael Shiraishi, Rahul Soangra, and Ehsan Rashedi
- Subjects
neurological disorder ,motion analysis ,inertial measurement unit ,stroke ,turning ,Chemical technology ,TP1-1185 - Abstract
Background: A stroke often bequeaths surviving patients with impaired neuromusculoskeletal systems subjecting them to increased risk of injury (e.g., due to falls) even during activities of daily living. The risk of injuries to such individuals can be related to alterations in their movement. Using inertial sensors to record the digital biomarkers during turning could reveal the relevant turning alterations. Objectives: In this study, movement alterations in stroke survivors (SS) were studied and compared to healthy individuals (HI) in the entire turning task due to its requirement of synergistic application of multiple bodily systems. Methods: The motion of 28 participants (14 SS, 14 HI) during turning was captured using a set of four Inertial Measurement Units, placed on their sternum, sacrum, and both shanks. The motion signals were segmented using the temporal and spatial segmentation of the data from the leading and trailing shanks. Several kinematic parameters, including the range of motion and angular velocity of the four body segments, turning time, the number of cycles involved in the turning task, and portion of the stance phase while turning, were extracted for each participant. Results: The results of temporal processing of the data and comparison between the SS and HI showed that SS had more cycles involved in turning, turn duration, stance phase, range of motion in flexion–extension, and lateral bending for sternum and sacrum (p-value < 0.035). However, HI exhibited larger angular velocity in flexion–extension for all four segments. The results of the spatial processing, in agreement with the prior method, showed no difference between the range of motion in flexion–extension of both shanks (p-value > 0.08). However, it revealed that the angular velocity of the shanks of leading and trailing legs in the direction of turn was more extensive in the HI (p-value < 0.01). Conclusions: The changes in upper/lower body segments of SS could be adequately identified and quantified by IMU sensors. The identified kinematic changes in SS, such as the lower flexion–extension angular velocity of the four body segments and larger lateral bending range of motion in sternum and sacrum compared to HI in turning, could be due to the lack of proper core stability and effect of turning on vestibular system of the participants. This research could facilitate the development of a targeted and efficient rehabilitation program focusing on the affected aspects of turning movement for the stroke community.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.